Yeonsue Jang
Research Subjects
Research Interests
Yeonsue Jang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Dong Suk Yoon
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 120-752, South Korea
5 shared publications- Jin Woo Lee
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, South Korea
5 shared publications Moses Lee
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 120-752, South Korea
3 shared publications- Baek Gil Kim
Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea
2 shared publications Kyoung-Mi Lee
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul 120-752, South Korea; Brain Korea 21 PLUS Project for Medical Sciences, Yonsei University College of Medicine, Seoul 120-752, South Korea
2 shared publications- Nam Hoon Cho
Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- 1 January 2020
- Published by Elsevier in Cancer Letters
- Vol. 469, 256-265
The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer
- 1 January 2020
- Published by Elsevier in Cancer Letters
- Vol. 469, 256-265
The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer
- 18 September 2019
- Published by Springer Nature in Oncogene
- Vol. 39 (3) , 664-676
ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts
Integrin beta 4 (ITGB4) overexpression in cancer cells contributes to cancer progression. However, the role of stromal ITGB4 expression in cancer progression remains poorly understood, despite stromal ITGB4 overexpression in malignant cancers. In our study, ITGB4-overexpressing triple negative breast cancer (TNBC) cells provided cancer-associated fibroblasts (CAFs) with ITGB4 proteins via exosomes, which induced BNIP3L-dependent mitophagy and lactate production in CAFs. In coculture assays, the ITGB4-induced mitophagy and glycolysis were suppressed in CAFs by knocking down ITGB4 or inhibiting exosome generation in MDA-MB-231, or blocking c-Jun or AMPK phosphorylation in CAFs. ITGB4-overexpressing CAF-conditioned medium promoted the proliferation, epithelial-to-mesenchymal transition, and invasion of breast cancer cells. In a co-transplant mouse model, MDA-MB-231 made a bigger tumor mass with CAFs than ITGB4 knockdown MDA-MB-231. Herein, we presented how TNBC-derived ITGB4 protein triggers glycolysis in CAFs via BNIP3L-dependent mitophagy and suggested the possibility that ITGB4-induced mitophagy could be targeted as a cancer therapy.
- 18 September 2019
- Published by Springer Nature in Oncogene
- Vol. 39 (3) , 664-676
ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts
Integrin beta 4 (ITGB4) overexpression in cancer cells contributes to cancer progression. However, the role of stromal ITGB4 expression in cancer progression remains poorly understood, despite stromal ITGB4 overexpression in malignant cancers. In our study, ITGB4-overexpressing triple negative breast cancer (TNBC) cells provided cancer-associated fibroblasts (CAFs) with ITGB4 proteins via exosomes, which induced BNIP3L-dependent mitophagy and lactate production in CAFs. In coculture assays, the ITGB4-induced mitophagy and glycolysis were suppressed in CAFs by knocking down ITGB4 or inhibiting exosome generation in MDA-MB-231, or blocking c-Jun or AMPK phosphorylation in CAFs. ITGB4-overexpressing CAF-conditioned medium promoted the proliferation, epithelial-to-mesenchymal transition, and invasion of breast cancer cells. In a co-transplant mouse model, MDA-MB-231 made a bigger tumor mass with CAFs than ITGB4 knockdown MDA-MB-231. Herein, we presented how TNBC-derived ITGB4 protein triggers glycolysis in CAFs via BNIP3L-dependent mitophagy and suggested the possibility that ITGB4-induced mitophagy could be targeted as a cancer therapy.
- 1 July 2016
- Published by Elsevier in Acta Biomaterialia
- Vol. 38, 59-68
Cell recruiting chemokine-loaded sprayable gelatin hydrogel dressings for diabetic wound healing
- 1 July 2016
- Published by Elsevier in Acta Biomaterialia
- Vol. 38, 59-68
Cell recruiting chemokine-loaded sprayable gelatin hydrogel dressings for diabetic wound healing
- 1 November 2014
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 51 (2) , 142-150
Characterization of adipose tissue-derived stromal vascular fraction for clinical application to cartilage regeneration
Bone marrow concentration (BMC) is the most recognized procedure to prepare mesenchymal stem cells for cartilage regeneration. However, bone marrow aspiration is highly invasive and results in low stem cell numbers. Recently, adipose tissue-derived stromal vascular fraction (AT-SVF) was studied as an alternate source of stem cells for cartilage regeneration. However, AT-SVF is not fully characterized in terms of functional equivalence to BMC. Therefore, in this study, we characterized AT-SVF and assessed its suitability as a one-step surgical procedure for cartilage regeneration, as an alternative to BMC. AT-SVF contained approximately sixfold less nucleated cells than BMC. However, adherent cells in AT-SVF were fourfold greater than BMC. Additionally, the colony-forming unit frequency of AT-SVF was higher than that of BMC, at 0.5 and 0.01%, respectively. The mesenchymal stem cell (MSC) population (CD45−CD31−CD90+CD105+) was 4.28% in AT-SVF and 0.42% in BMC, and the adipose-derived stromal cell (ASC) population (CD34+CD31−CD146−) was 32% in AT-SVF and 0.16% in BMC. In vitro chondrogenesis demonstrated that micromass was not formed in BMC, whereas it was clearly formed in AT-SVF. Taken together, uncultured AT-SVF could be used in one-step surgery for cartilage regeneration as a substitute for BMC.
- 1 November 2014
- Published by Springer Nature in In Vitro Cellular & Developmental Biology - Animal
- Vol. 51 (2) , 142-150
Characterization of adipose tissue-derived stromal vascular fraction for clinical application to cartilage regeneration
Bone marrow concentration (BMC) is the most recognized procedure to prepare mesenchymal stem cells for cartilage regeneration. However, bone marrow aspiration is highly invasive and results in low stem cell numbers. Recently, adipose tissue-derived stromal vascular fraction (AT-SVF) was studied as an alternate source of stem cells for cartilage regeneration. However, AT-SVF is not fully characterized in terms of functional equivalence to BMC. Therefore, in this study, we characterized AT-SVF and assessed its suitability as a one-step surgical procedure for cartilage regeneration, as an alternative to BMC. AT-SVF contained approximately sixfold less nucleated cells than BMC. However, adherent cells in AT-SVF were fourfold greater than BMC. Additionally, the colony-forming unit frequency of AT-SVF was higher than that of BMC, at 0.5 and 0.01%, respectively. The mesenchymal stem cell (MSC) population (CD45−CD31−CD90+CD105+) was 4.28% in AT-SVF and 0.42% in BMC, and the adipose-derived stromal cell (ASC) population (CD34+CD31−CD146−) was 32% in AT-SVF and 0.16% in BMC. In vitro chondrogenesis demonstrated that micromass was not formed in BMC, whereas it was clearly formed in AT-SVF. Taken together, uncultured AT-SVF could be used in one-step surgery for cartilage regeneration as a substitute for BMC.
- Open Access
- 7 August 2014
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 32 (12) , 3219-3231
SIRT1 Directly Regulates SOX2 to Maintain Self-Renewal and Multipotency in Bone Marrow-Derived Mesenchymal Stem Cells
SOX2 is crucial for the maintenance of the self-renewal capacity and multipotency of mesenchymal stem cells (MSCs); however, the mechanism by which SOX2 is regulated remains unclear. Here, we report that RNA interference of sirtuin 1 (SIRT1) in human bone marrow (BM)-derived MSCs leads to a decrease of SOX2 protein, resulting in the deterioration of the self-renewal and differentiation capacities of BM-MSCs. Using immunoprecipitation, we demonstrated direct binding between SIRT1 and SOX2 in HeLa cells overexpressing SOX2. We further discovered that the RNA interference of SIRT1 induces the acetylation, nuclear export, and ubiquitination of SOX2, leading to proteasomal degradation in BM-MSCs. SOX2 suppression by trichostatin A (TSA), a known histone deacetylase inhibitor, was reverted by treatment with resveratrol (0.1 and 1 µM), a known activator of SIRT1 in BM-MSCs. Furthermore, 0.1 and 1 µM resveratrol reduced TSA-mediated acetylation and ubiquitination of SOX2 in BM-MSCs. SIRT1 activation by resveratrol enhanced the colony-forming ability and differentiation potential to osteogenic and adipogenic lineages in a dose-dependent manner. However, the enhancement of self-renewal and multipotency by resveratrol was significantly decreased to basal levels by RNA interference of SOX2. These results strongly suggest that the SIRT1-SOX2 axis plays an important role in maintaining the self-renewal capability and multipotency of BM-MSCs. In conclusion, our findings provide evidence for positive SOX2 regulation by post-translational modification in BM-MSCs through the inhibition of nuclear export and subsequent ubiquitination, and demonstrate that SIRT1-mediated deacetylation contributes to maintaining SOX2 protein in the nucleus. Stem Cells 2014;32:3219–3231
- 7 August 2014
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 32 (12) , 3219-3231
Open AccessSIRT1 Directly Regulates SOX2 to Maintain Self-Renewal and Multipotency in Bone Marrow-Derived Mesenchymal Stem Cells
SOX2 is crucial for the maintenance of the self-renewal capacity and multipotency of mesenchymal stem cells (MSCs); however, the mechanism by which SOX2 is regulated remains unclear. Here, we report that RNA interference of sirtuin 1 (SIRT1) in human bone marrow (BM)-derived MSCs leads to a decrease of SOX2 protein, resulting in the deterioration of the self-renewal and differentiation capacities of BM-MSCs. Using immunoprecipitation, we demonstrated direct binding between SIRT1 and SOX2 in HeLa cells overexpressing SOX2. We further discovered that the RNA interference of SIRT1 induces the acetylation, nuclear export, and ubiquitination of SOX2, leading to proteasomal degradation in BM-MSCs. SOX2 suppression by trichostatin A (TSA), a known histone deacetylase inhibitor, was reverted by treatment with resveratrol (0.1 and 1 µM), a known activator of SIRT1 in BM-MSCs. Furthermore, 0.1 and 1 µM resveratrol reduced TSA-mediated acetylation and ubiquitination of SOX2 in BM-MSCs. SIRT1 activation by resveratrol enhanced the colony-forming ability and differentiation potential to osteogenic and adipogenic lineages in a dose-dependent manner. However, the enhancement of self-renewal and multipotency by resveratrol was significantly decreased to basal levels by RNA interference of SOX2. These results strongly suggest that the SIRT1-SOX2 axis plays an important role in maintaining the self-renewal capability and multipotency of BM-MSCs. In conclusion, our findings provide evidence for positive SOX2 regulation by post-translational modification in BM-MSCs through the inhibition of nuclear export and subsequent ubiquitination, and demonstrate that SIRT1-mediated deacetylation contributes to maintaining SOX2 protein in the nucleus. Stem Cells 2014;32:3219–3231
- Open Access
- 9 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (7) , 3273-3286
Interleukin‐6 induces the lineage commitment of bone marrow‐derived mesenchymal multipotent cells through down‐regulation of Sox2 by osteogenic transcription factors
Bone marrow‐derived mesenchymal stromal cells (BM‐MSCs) are a heterogeneous population of cells that differ in size and morphology. BM‐MSCs become committed to the osteogenic lineage as senescence approaches and lose multipotency. Nevertheless, little is known about the effects of cell‐cell interaction between different populations on stemness loss and lineage commitment. The current study aimed to identify mechanisms by which cell‐cell interactions between heterogeneous BM‐MSCs affect stemness and lineage commitment of multipotent subpopulation. The lineage commitment of primitive multipotent cells was strongly induced in the presence of cytokines secreted by senescent‐like cells in a cell culture insert system. Senescent‐like cells secreted higher levels of interleukin‐6 (IL‐6) than primitive multipotent cells in a human cytokine array. IL‐6 induced the lineage commitment and stemness loss in multipotent cells by decreasing Sox2 expression. Furthermore, we confirmed that IL‐6 decreased the transcriptional activity of Sox2 through up‐regulation of Runx2 and Dlx5. We suggest a mechanism by which IL‐6 modulates the expression of Sox2, resulting in decreased multipotency and causing primitive multipotent cells to undergo osteogenic lineage commitment. This is the first study to identify mechanisms in which the cell‐cell interactions between the different populations play important roles in the stemness loss and lineage commitment of multipotent populations.—Yoon, D. S., Kim, Y. H., Lee, S., Lee, K.‐M., Park, K. H., Jang, Y., Lee, J. W. Interleukin‐6 induces the lineage commitment of bone marrow‐derived mesenchymal multipotent cells through down‐regulation of Sox2 by osteogenic transcription factors. FASEB J . 28, 3273–3286 (2014). www.fasebj.org
- 9 April 2014
- Published by Wiley in The FASEB Journal
- Vol. 28 (7) , 3273-3286
Open AccessInterleukin‐6 induces the lineage commitment of bone marrow‐derived mesenchymal multipotent cells through down‐regulation of Sox2 by osteogenic transcription factors
Bone marrow‐derived mesenchymal stromal cells (BM‐MSCs) are a heterogeneous population of cells that differ in size and morphology. BM‐MSCs become committed to the osteogenic lineage as senescence approaches and lose multipotency. Nevertheless, little is known about the effects of cell‐cell interaction between different populations on stemness loss and lineage commitment. The current study aimed to identify mechanisms by which cell‐cell interactions between heterogeneous BM‐MSCs affect stemness and lineage commitment of multipotent subpopulation. The lineage commitment of primitive multipotent cells was strongly induced in the presence of cytokines secreted by senescent‐like cells in a cell culture insert system. Senescent‐like cells secreted higher levels of interleukin‐6 (IL‐6) than primitive multipotent cells in a human cytokine array. IL‐6 induced the lineage commitment and stemness loss in multipotent cells by decreasing Sox2 expression. Furthermore, we confirmed that IL‐6 decreased the transcriptional activity of Sox2 through up‐regulation of Runx2 and Dlx5. We suggest a mechanism by which IL‐6 modulates the expression of Sox2, resulting in decreased multipotency and causing primitive multipotent cells to undergo osteogenic lineage commitment. This is the first study to identify mechanisms in which the cell‐cell interactions between the different populations play important roles in the stemness loss and lineage commitment of multipotent populations.—Yoon, D. S., Kim, Y. H., Lee, S., Lee, K.‐M., Park, K. H., Jang, Y., Lee, J. W. Interleukin‐6 induces the lineage commitment of bone marrow‐derived mesenchymal multipotent cells through down‐regulation of Sox2 by osteogenic transcription factors. FASEB J . 28, 3273–3286 (2014). www.fasebj.org
- 24 March 2014
- Published by SAGE Publications in Stem Cells and Development
- Vol. 23 (15) , 1798-1808
microRNA-495 Inhibits Chondrogenic Differentiation in Human Mesenchymal Stem Cells by Targeting Sox9
The chondrogenic differentiation process of human mesenchymal stem cells (hMSCs) passes through multiple stages, which are carried out by various factors and their interactions. Recently, microRNAs that regulate chondrogenic differentiation have been reported. However, microRNA that regulates SRY-related high mobility group-box gene 9 (Sox9), a chondrogenic key factor, has not been identified in hMSC. In this study, we identified that microRNA-495 (miR-495) is an important regulator of hMSC chondrogenic differentiation. In our microarray, miR-495 was downregulated during transforming growth factor (TGF)-β3-induced chondrogenic differentiation of hMSCs in vitro. We found that there is an miR-495 binding site in the 3′ untranslated region (3′UTR) of Sox9 . We confirmed opposite expression between miR-495 and Sox9 by using real-time polymerase chain reaction. Further, overexpression of miR-495 inhibited Sox9 expression, and repression of miR-495 increased expression of Sox9 in SW1353 cells and hMSCs. Additionally, luciferase analysis revealed that miR-495 directly binds to the Sox9 3′UTR, and we confirmed a seed sequence of miR-495 on the Sox9 3′UTR. Subsequently, overexpression of miR-495 repressed the expression of the extracellular matrix (ECM) protein, such as type II collagen (Col2A1), aggrecan, and proteoglycan products, whereas inhibition of miR-495 increased their expression. Collectively, this study indicates that miR-495 directly targets Sox9, ultimately leading to the regulation of chondrogenic differentiation in hMSCs.
- 24 March 2014
- Published by SAGE Publications in Stem Cells and Development
- Vol. 23 (15) , 1798-1808
microRNA-495 Inhibits Chondrogenic Differentiation in Human Mesenchymal Stem Cells by Targeting Sox9
The chondrogenic differentiation process of human mesenchymal stem cells (hMSCs) passes through multiple stages, which are carried out by various factors and their interactions. Recently, microRNAs that regulate chondrogenic differentiation have been reported. However, microRNA that regulates SRY-related high mobility group-box gene 9 (Sox9), a chondrogenic key factor, has not been identified in hMSC. In this study, we identified that microRNA-495 (miR-495) is an important regulator of hMSC chondrogenic differentiation. In our microarray, miR-495 was downregulated during transforming growth factor (TGF)-β3-induced chondrogenic differentiation of hMSCs in vitro. We found that there is an miR-495 binding site in the 3′ untranslated region (3′UTR) of Sox9 . We confirmed opposite expression between miR-495 and Sox9 by using real-time polymerase chain reaction. Further, overexpression of miR-495 inhibited Sox9 expression, and repression of miR-495 increased expression of Sox9 in SW1353 cells and hMSCs. Additionally, luciferase analysis revealed that miR-495 directly binds to the Sox9 3′UTR, and we confirmed a seed sequence of miR-495 on the Sox9 3′UTR. Subsequently, overexpression of miR-495 repressed the expression of the extracellular matrix (ECM) protein, such as type II collagen (Col2A1), aggrecan, and proteoglycan products, whereas inhibition of miR-495 increased their expression. Collectively, this study indicates that miR-495 directly targets Sox9, ultimately leading to the regulation of chondrogenic differentiation in hMSCs.